PR-957, a selective immunoproteasome inhibitor, reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1.

In conclusion, the immunoproteasome inhibitor PR-957 is a promising candidate LRA for future HIV-1 eradication strategies.
PMID: 30170098 [PubMed - as supplied by publisher]

Source: Biochemical Pharmacology - August 28, 2018 Category: Drugs & Pharmacology Authors: Lin J, Zhang X, Lu W, Xu X, Pan X, Liang T, Duan S, Chen Y, Li L, Liu S Tags: Biochem Pharmacol Source Type: research